<div id="readability-page-1"><p>Edmond DE Rothschild Holding S.A. decreased its position in shares of  Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 38.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,366,200 shares of the biotechnology company's stock after selling 8,488,980 shares during the quarter. Edmond DE Rothschild Holding S.A. owned approximately 4.45% of Pacific Biosciences of California worth $16,574,000 as of its most recent filing with the SEC.</p><ul><li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li></ul><p>Several other institutional investors and hedge funds have also made changes to their positions in PACB. Prudential Financial Inc. boosted its position in shares of  Pacific Biosciences of California by 73.0% in the 2nd quarter. Prudential Financial Inc. now owns 35,684 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 15,062 shares during the period.  Cetera Investment Advisers lifted its stake in  Pacific Biosciences of California by 10.1% in the second quarter. Cetera Investment Advisers now owns 104,725 shares of the biotechnology company's stock valued at $130,000 after buying an additional 9,617 shares during the last quarter.  Creative Planning lifted its stake in  Pacific Biosciences of California by 245.9% in the second quarter. Creative Planning now owns 175,690 shares of the biotechnology company's stock valued at $218,000 after buying an additional 124,893 shares during the last quarter.  Geode Capital Management LLC boosted its holdings in shares of  Pacific Biosciences of California by 6.4% in the second quarter. Geode Capital Management LLC now owns 6,718,879 shares of the biotechnology company's stock valued at $8,333,000 after acquiring an additional 401,637 shares during the period.  Finally, Vestmark Advisory Solutions Inc. grew its position in shares of  Pacific Biosciences of California by 89.9% during the second quarter. Vestmark Advisory Solutions Inc. now owns 1,294,186 shares of the biotechnology company's stock worth $1,605,000 after acquiring an additional 612,760 shares during the last quarter. </p><h2>Pacific Biosciences of California Trading Up 12.6%</h2><p>Shares of Pacific Biosciences of California stock opened at $2.50 on Tuesday. The firm has a market cap of $754.77 million, a price-to-earnings ratio of -1.09 and a beta of 2.30. Pacific Biosciences of California, Inc. has a 52-week low of $0.85 and a 52-week high of $2.53. The company's 50-day simple moving average is $1.67 and its 200-day simple moving average is $1.42. The company has a quick ratio of 6.02, a current ratio of 6.92 and a debt-to-equity ratio of 10.51. </p><ul><li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li></ul><p>Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last announced its quarterly earnings data on Wednesday, March 29th. The biotechnology company reported ($0.23) EPS for the quarter. The firm had revenue of $3.34 million during the quarter. Pacific Biosciences of California had a negative net margin of 336.40% and a negative return on equity of 66.75%.  As a group, equities research analysts anticipate that  Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>PACB has been the subject of several research reports. Piper Sandler upped their price target on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the company a &#34;neutral&#34; rating in a research report on Tuesday, November 11th. Wall Street Zen raised shares of Pacific Biosciences of California from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 9th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Pacific Biosciences of California in a research note on Wednesday, October 8th. Finally, Stephens raised their price target on Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an &#34;overweight&#34; rating in a report on Monday, November 10th. Three investment analysts have rated the stock with a Buy rating, three have issued  a Hold rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Pacific Biosciences of California  has an average rating of &#34;Hold&#34; and a consensus price target of $2.00.</p><p><b>Get Our Latest Report on PACB</b></p><h2>Pacific Biosciences of California Company Profile</h2> (Free Report)<p>Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.</p><h2>See Also</h2><ul><li>Five stocks we like better than Pacific Biosciences of California</li><li>What is the S&amp;P/TSX Index?</li><li>D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?</li><li>What does consumer price index measure? </li><li>Hims, Block, and NRG Just Launched Huge Stock Buybacks </li><li>10 Best Airline Stocks to Buy</li><li>Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3</li></ul><p><strong>Want to see what other hedge funds are holding PACB?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFDQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFDQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pacific Biosciences of California Right Now?</h2><p>Before you consider Pacific Biosciences of California, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacific Biosciences of California wasn't on the list.</p><p>While Pacific Biosciences of California currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PACB

<p>Edmond DE Rothschild Holding S.A. reduced its stake in Pacific Biosciences of California, Inc. by 38.8% in Q2, selling 8,488,980 shares. The fund now holds 13,366,200 shares, worth $16,574,000. Other institutional investors also adjusted their positions. PACB shares rose 12.6%, opening at $2.50. Analysts have mixed ratings, with a consensus price target of $2.00.</p>

Pacific Biosciences of California, Inc. $PACB Shares Sold by Edmond DE Rothschild Holding S.A.